Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Bristol-Myers Squibb Massachusetts General Hospital Beth Israel Deaconess Medical Center |
---|---|
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00130689 |
The purpose of this study is to determine the response rate of cetuximab in patients with advanced esophageal or gastric cancer.
The secondary purposes are to determine the safety and to evaluate the duration of response in patients treated with cetuximab.
Condition | Intervention | Phase |
---|---|---|
Esophageal Cancer Gastric Cancer Neoplasm Metastasis |
Drug: Cetuximab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial of Cetuximab in Unresectable or Metastatic Esophageal and Gastric Carcinoma |
Estimated Enrollment: | 36 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Cetuximab will be administered to the patient once weekly until disease progression or development of toxicity preclude further treatment. One treatment cycle is considered 4 weeks. While receiving cetuximab, the patients' vitals will be monitored weekly, every 4 weeks (1 cycle), bloodwork and a physical exam will be performed and every 8 weeks (2 cycles), reassessment of the tumor and urine pregnancy test for women patients of childbearing potential will be performed.
All patients will be evaluated by history and physical exam at the end of the study treatment.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jennifer Chan, MD | 617-632-6315 |
United States, Massachusetts | |
Dana-Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Dana-Farber/Harvard Cancer Center Clinical Trial Matching Service 866-790-4500 | |
Principal Investigator: Jennifer Ang Chan, MD | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Dana-Farber/Harvard Cancer Center Clinical Trial Matching Service 866-790-4500 | |
Sub-Investigator: David Ryan, MD | |
Beth Israel Deaconess Medical Center | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Dana-Farber/Harvard Cancer Center Clinical Trial Matching Service 866-790-4500 | |
Sub-Investigator: Sanjay Jain, MD | |
North Shore Medical Center Cancer Center | Recruiting |
Peabody, Massachusetts, United States |
Principal Investigator: | Jennifer Ang Chan, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Jennifer Ang Chan, MD ) |
Study ID Numbers: | 05-113 |
Study First Received: | August 15, 2005 |
Last Updated: | December 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00130689 |
Health Authority: | United States: Food and Drug Administration |
Esophageal Cancer Gastric Cancer Metastatic Esophageal Cancer |
Metastatic Gastric Cancer Cetuximab Metastatic Esophageal and Gastric Cancer |
Digestive System Neoplasms Esophageal disorder Gastrointestinal Diseases Esophageal Neoplasms Cetuximab Stomach cancer Carcinoma Digestive System Diseases |
Stomach Diseases Stomach Neoplasms Head and Neck Neoplasms Neoplasm Metastasis Gastrointestinal Neoplasms Esophageal Diseases Esophageal neoplasm |
Neoplastic Processes Neoplasms Pathologic Processes Neoplasms by Site |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |